Posters

Clinical outcomes after implantation of a posterior chamber collamer phakic intraocular lens: a retrospective 2-year follow-up study

Poster Details

First Author: N.Quesnel CANADA

Co Author(s):    F. Roy   C. Ieraci                 

Abstract Details

Purpose:

To retrospectively assess the clinical outcomes of spherical and toric implantable collamer lenses (ICL), model EVO or EVO+. The study was conducted in a private refractive surgery clinic 2 years after the first implantation in 2017.

Setting:

Iris Ophthalmology Clinic , Quebec, Canada

Methods:

This study was a retrospective review of the medical records of 35 myopic patients who had bilateral ICL implantation by one surgeon from August 2017. The records were reviewed from the 24-Hour postoperative evaluation up to the 2-Year follow-up. The preoperative and postoperative (uncorrected and best corrected) visual acuity (UCVA and BCVA) as well as endothelial cell density were evaluated. The changes of the postoperative vault measured during follow-ups were analysed. The safety, efficacy, predictability and adverse events at 3 months (62 eyes), 12 months (38 eyes) and 2 years (6 eyes) were assessed

Results:

At 1-Year, the mean logMar UCVA was -0.0363±0.079. 93% of eyes achieved the same or better UCVA as their preoperative BCVA. 30% of eyes gain at least 1 line. 97% of eyes were within 1.0D of attempted correction. The mean vault was 517±217 microns at 24-hour postop compared to 479±200 at 3 months and 401±210 at 1-year. The mean vault decreases by 41 between the 24-hour measurement and the 1-year. Mean endothelial cell loss was 0.81%±0,08%. No vision-threatening complications occurred. Four eyes (6%) required a change in ICL secondary to rotation and low vault and 3 eyes required a PRK.

Conclusions:

ICL implantation in this group of patients offered good overall outcomes in all measures of safety, efficacy, predictability and stability for the correction of myopia and myopic astigmatism throughout the follow-up period. Since the vault continue to decrease between 3 months and one year postop and up to 2 years after implantation, it is important to closely monitor all patients.

Financial Disclosure:

None